Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Availability of genome-matched therapy based on clinical practice.
Hayashi N, Mori S, Ohmoto A, Fukada I, Yamazaki M, Hosonaga M, Wang X, Ueki A, Kiyotani K, Tonooka A, Takeuchi K, Takahashi S. Hayashi N, et al. Among authors: fukada i. Int J Clin Oncol. 2024 Apr 26. doi: 10.1007/s10147-024-02533-z. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38668785
Assessment of a cancer genomic profile test for patients with metastatic breast cancer.
Fukada I, Mori S, Hayashi N, Hosonaga M, Yamazaki M, Wang X, Kawai S, Inagaki L, Ozaki Y, Kobayashi K, Hara F, Kobayashi T, Ueki A, Osako T, Tonooka A, Takeuchi K, Ueno T, Takano T, Ohno S, Takahashi S. Fukada I, et al. Sci Rep. 2022 Mar 21;12(1):4813. doi: 10.1038/s41598-022-08925-3. Sci Rep. 2022. PMID: 35315838 Free PMC article.
Druggable gene alterations in Japanese patients with rare malignancy.
Ohmoto A, Hayashi N, Fukada I, Yamazaki M, Yunokawa M, Kasuga A, Shinozaki E, Ueki A, Tonooka A, Takeuchi K, Mori S, Kiyotani K, Takahashi S. Ohmoto A, et al. Among authors: fukada i. Neoplasia. 2022 Nov;33:100834. doi: 10.1016/j.neo.2022.100834. Epub 2022 Sep 8. Neoplasia. 2022. PMID: 36088851 Free PMC article.
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
Ozaki Y, Aoyama Y, Masuda J, Inagaki L, Kawai S, Shibayama T, Maeda T, Kurata M, Yoshida K, Saeki S, Hosonaga M, Fukada I, Hara F, Kobayashi T, Kobayashi K, Miyake S, Takano T, Ueno T, Ohno S. Ozaki Y, et al. Among authors: fukada i. BMC Cancer. 2022 Jan 4;22(1):36. doi: 10.1186/s12885-021-09128-1. BMC Cancer. 2022. PMID: 34983437 Free PMC article.
Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Araki K, Fukada I, Horii R, Takahashi S, Akiyama F, Iwase T, Ito Y. Araki K, et al. Among authors: fukada i. Breast Cancer Res Treat. 2014 Nov;148(1):197-209. doi: 10.1007/s10549-014-3148-7. Epub 2014 Oct 1. Breast Cancer Res Treat. 2014. PMID: 25270122
31 results